Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer treatment reports|
|State||Published - 1982|
ASJC Scopus subject areas
- Cancer Research